AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-11. (cancelled)

- 12. (currently amended) A method for producing a human or animal plasma product, or serum product comprising the following steps (a) and (b):
- (a) a step of separating plasma from the whole blood originating from a human or animal and reducing leukocytes in the plasma and
- (b) a step of filtering the plasma using a virus removal membrane after the step (a).
- 13. (currently amended) A method for producing a human or animal plasma product, or a serum product comprising the following steps (a) and (b):
- (a) a step of separating plasma from the whole blood originating from a human or animal immediately after collection of the blood and reducing leukocytes in the plasma immediately after the above separation and
- (b) a step of filtering using a virus removal membrane after the step (a).

- 14. (currently amended) [[A]] The method according to claim 12, wherein a raw material plasma that is separated from the whole blood or plasma which is further reduced with leukocytes for producing the plasma product or serum product is has not been frozen before virus removal filtration in step (b).
- 15. (currently amended) [[A]] The method according to claim 12, wherein step (a) comprises separating plasma from the whole blood originating from a human or animal within four hours from collection of the blood and reducing leukocytes in plasma immediately after said separation, and in step (b) a raw material for producing the plasma product or scrum-product is not frozen before virus removal filtration.

16. (cancelled)

- 17. (currently amended) [[A]] The method according to claim 12, wherein the plasma product or serum product is a fresh frozen plasma.
- 18. (currently amended) [[A]] The method according to claim 13, wherein "immediately" means the step (a) is performed within four hours after collection of the blood.

- 19. (currently amended) [[A]] The method according to claim 15, wherein "immediately" means the step (a) is performed within two hours after collection of the blood.
- 20. (previously presented) The method according to claim 12, wherein the virus removal membrane used in step (b) has an average pore diameter of 100 nm or less.
- 21. (previously presented) The method according to claim 12, wherein the step (a) is a leukocyte-reducing step using a leukocyte removal membrane.
- 22. (currently amended) The method according to claim 12, wherein the steps (a) and (b) are carried out under the condition of a temperature of $25-40^{\circ}$ C.
- 23. (currently amended) The method according to claim 12, wherein the steps (a) and (b) are carried out under the condition of a pressure of 98 kPa or less.
- 24. (currently amended) The method according to claim 12, wherein [[the]] amounts of blood in step (a) and plasma reduced with leukocytes in step (b) passing through in the steps (a) and (b) are 100-500 ml, respectively.

- 25. (currently amended) The method according to claim 12, wherein [[the]] \underline{a} treatment time for the step (b) is 40 minutes or less.
- 26. (previously presented) The method according to claim 12, wherein the virus removal membrane used in the step (b) has an average pore diameter of 75 nm or less.
- 27. (previously presented) The method according to claim 12, wherein the virus removal membrane used in the step (b) is a combination of a virus removal membrane having an average pore diameter of 75 nm and another virus removal membrane having an average pore diameter of 35 nm subsequent to the former membrane.
- 28. (withdrawn) A human or animal plasma product or a serum product produced by a method comprising the following steps (a) and (b):
- (a) a step of separating plasma from the whole blood originating from a human or animal and reducing leukocytes in the plasma and
- (b) a step of filtering using a virus removal membrane after the step (a).

29. (currently amended) [[A]] The method according to claim 13, wherein a raw material plasma that is separated from the whole blood or plasma which is further reduced with leukocytes for producing the plasma product or serum product is has not been frozen before virus removal filtration in step [[(□)]] (b).

30. (cancelled)